Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BRII-179 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BRII-179 (longer dose interval) followed by BRII-835 + PEG-IFNα | EXPERIMENTAL | Participants will receive BRII-179 of a longer dose interval, followed by BRII-835 and PEG-IFNα combination therapy. |
| BRII-179 (shorter dose interval) followed by BRII-835 + PEG-IFNα | EXPERIMENTAL | Participants will receive BRII-179 of a shorter dose interval, followed by BRII-835 and PEG-IFNα combination therapy. |
| Name | Type | Description |
|---|---|---|
| BRII-179 | BIOLOGICAL | BRII-179 will be given via intramuscular injection |
| BRII-835 (VIR-2218) | DRUG | BRII-835 will be given via subcutaneous injection |
| PEG-IFNα | BIOLOGICAL | PEG-IFNα will be given via subcutaneous injection |
Inclusion Criteria: * 1\. Male or female aged 18-60 years. * 2\. Body mass index ≥ 18 kg/m2 and ≤ 32 kg/m2. * 3\. Chronic HBV infection for ≥ 6 months. * 4\. On NRTI therapy for ≥ 6 months. Exclusion Criteria: * 1\. Any clinically significant chronic or acute medical condition that makes the part...
BRII-179 is an investigational monoclonal antibody being developed for the treatment of chronic hepatitis B virus (HBV) infection. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
BRII-179 is being developed by Vir Biotechnology, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VIR. The company is conducting clinical trials to evaluate the safety and efficacy of BRII-179 in patients with chronic hepatitis B.
BRII-179 is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. The ongoing Phase 2 trial is evaluating the drug in combination with other therapies for chronic hepatitis B virus infection.
BRII-179 is being studied in a Phase 2 clinical trial identified as NCT06491563, titled 'Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH).' The trial is active but not recruiting, with an enrollment of 150 participants in China.
Yes, BRII-179 is being evaluated in combination with BRII-835 and PEG-IFNα in a Phase 2 clinical trial for chronic hepatitis B virus infection. The study is designed to investigate the efficacy and safety of these regimens, and it is being conducted in China.